{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:44:10Z","timestamp":1794653050812,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-025-01735-x","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T10:04:42Z","timestamp":1763719482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic value of manual and digital PD-L1 expression in pT3 and pT4 colon cancer"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-6350","authenticated-orcid":false,"given":"Dea Natalie Munch","family":"Jepsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne B\u00f8gevang","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-0985","authenticated-orcid":false,"given":"Astrid Louise Bj\u00f8rn","family":"Bennedsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-2948","authenticated-orcid":false,"given":"Trine L\u00f8nbo","family":"Grantzau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-6190","authenticated-orcid":false,"given":"Thomas Thiilmark","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-5018","authenticated-orcid":false,"given":"Jens Ole","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-5856","authenticated-orcid":false,"given":"Michael","family":"Bzorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-268X","authenticated-orcid":false,"given":"Ismail","family":"G\u00f6genur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1741-1140","authenticated-orcid":false,"given":"Anne-Marie Kanstrup","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1735_CR1","first-page":"167","volume":"17","author":"X Jiang","year":"2025","unstructured":"Jiang X, Zhan Y, Yang D-H, Bao L. Immunotherapy in gastrointestinal cancers: current insights. Clin Pharmacol. 2025;17:167\u201383.","journal-title":"Clin Pharmacol"},{"key":"1735_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"1735_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-021-01151-x","volume":"16","author":"M Akhtar","year":"2021","unstructured":"Akhtar M, Rashid S, Al-Bozom IA. PD-L1 immunostaining: what pathologists need to know. Diagn Pathol. 2021;16:94.","journal-title":"Diagn Pathol"},{"key":"1735_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101851","volume":"40","author":"X Chen","year":"2024","unstructured":"Chen X, Chen L-J, Peng X-F, Deng L, Wang Y, Li J-J, et al. Anti-PD-1\/PD-L1 therapy for colorectal cancer: clinical implications and future considerations. Transl Oncol. 2024;40:101851.","journal-title":"Transl Oncol"},{"key":"1735_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006369","volume":"96","author":"Q Wang","year":"2017","unstructured":"Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore). 2017;96:e6369.","journal-title":"Medicine (Baltimore)"},{"key":"1735_CR6","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.5301\/jbm.5000225","volume":"32","author":"J-S Pyo","year":"2017","unstructured":"Pyo J-S, Kang G, Kim JY. Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. Int J Biol Markers. 2017;32:e68-74.","journal-title":"Int J Biol Markers"},{"key":"1735_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.5114\/pjp.2022.125537","volume":"73","author":"AE Yeti\u015fir","year":"2022","unstructured":"Yeti\u015fir AE, Payda\u015f S, G\u00f6nl\u00fc\u015fen G, Erdo\u011fan KE, B\u00fcy\u00fck\u015fim\u015fek M, O\u011ful A, et al. Sarcoma - correlation between CD73 and PD-L1 and their relationship with prognosis. Pol J Pathol. 2022;73:338\u201342.","journal-title":"Pol J Pathol"},{"key":"1735_CR8","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1735_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09169-0","author":"ALB Bennedsen","year":"2022","unstructured":"Bennedsen ALB, Cai L, Hasselager RP, \u00d6zcan AA, Mohamed KB, Eriksen JO, et al. An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer. BMC Cancer. 2022. https:\/\/doi.org\/10.1186\/s12885-022-09169-0.","journal-title":"BMC Cancer"},{"key":"1735_CR10","unstructured":"NordicQC\u2019s assessment run C17 2025 PD-L1 TPS\/CPS. https:\/\/www.nordiqc.org\/downloads\/assessments\/206_110.pdf. Acessed Oct 31 2015."},{"key":"1735_CR11","unstructured":"PD-L1 IHC 22\u00a0C. 3 pharmDx Interpretation Manual \u2013 Gastric or Gastroesophageal Junction Adenocarcinoma. https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29613-d0039853-22c3-pharmdx-gastric-interpretation-manual-us.pdf. Accessed Oct 31 2025."},{"key":"1735_CR12","unstructured":"https:\/\/visiopharm.com\/app-center\/app\/nuclei-detection-ai-brightfield\/. Accessed Sept 25 2025."},{"key":"1735_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","volume":"80","author":"DY Lin","year":"1993","unstructured":"Lin DY, Wei L-J, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557\u201372.","journal-title":"Biometrika"},{"key":"1735_CR14","unstructured":"Therneau T. A package for survival analysis in R. R package version 3.8-3. 2024. https:\/\/cran.r-project.org\/package=survival"},{"key":"1735_CR15","unstructured":"Kassambara A, Kosinski M, Biecek P, survminer. Drawing Survival Curves using \u2018ggplot2\u2019. R package version 0.5.1. 2025. https:\/\/cran.r-project.org\/package=survminer"},{"key":"1735_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.csda.2015.01.014","volume":"93","author":"KK Holst","year":"2016","unstructured":"Holst KK, Scheike TH, Hjelmborg JB. The liability threshold model for censored twin data. Comput Stat Data Anal. 2016;93:324\u201335.","journal-title":"Comput Stat Data Anal"},{"key":"1735_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10985-013-9244-x","volume":"20","author":"TH Scheike","year":"2014","unstructured":"Scheike TH, Holst KK, Hjelmborg JB. Estimating heritability for cause specific mortality based on twin studies. Lifetime Data Anal. 2014;20:210\u201333.","journal-title":"Lifetime Data Anal"},{"key":"1735_CR18","doi-asserted-by":"publisher","first-page":"103147","DOI":"10.1016\/j.critrevonc.2020.103147","volume":"157","author":"PG Alexander","year":"2021","unstructured":"Alexander PG, McMillan DC, Park JH. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. Crit Rev Oncol Hematol. 2021;157:103147.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1735_CR19","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1038\/s41379-022-01128-1","volume":"35","author":"O Y\u0131lmaz","year":"2022","unstructured":"Y\u0131lmaz O, Pankaj A, Neyez A, Rickelt S, Taylor M, Lang ER, et al. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma. Mod Pathol. 2022;35:1740\u20138.","journal-title":"Mod Pathol"},{"key":"1735_CR20","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41379-019-0219-7","volume":"32","author":"M Ahtiainen","year":"2019","unstructured":"Ahtiainen M, Wirta E-V, Kuopio T, Sepp\u00e4l\u00e4 T, Rantala J, Mecklin J-P, et al. Combined prognostic value of CD274 (PD-L1)\/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status. Mod Pathol. 2019;32:866\u201383.","journal-title":"Mod Pathol"},{"key":"1735_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00262-017-1999-6","volume":"66","author":"KS Lee","year":"2017","unstructured":"Lee KS, Kwak Y, Ahn S, Shin E, Oh H-K, Kim D-W, et al. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol Immunother. 2017;66:927\u201339.","journal-title":"Cancer Immunol Immunother"},{"key":"1735_CR22","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","volume":"49","author":"RA Droeser","year":"2013","unstructured":"Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 2013;49:2233\u201342.","journal-title":"Eur J Cancer"},{"key":"1735_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041228","volume":"104","author":"KY Jang","year":"2025","unstructured":"Jang KY, Kim KM, Ha GW, Lee MR, Park HS, Chung MJ, et al. PD-L1 and ALK expressions in stages III and IV colorectal cancer and their correlation with clinicopathological features. Medicine (Baltimore). 2025;104:e41228.","journal-title":"Medicine (Baltimore)"},{"key":"1735_CR24","doi-asserted-by":"publisher","first-page":"9647","DOI":"10.3390\/curroncol30110699","volume":"30","author":"J Liu","year":"2023","unstructured":"Liu J, Li J, Luo F, Wu S, Li B, Liu K. The predictive value of CD3+\/CD8\u2009+\u2009lymphocyte infiltration and PD-L1 expression in colorectal cancer. Curr Oncol. 2023;30:9647\u201359.","journal-title":"Curr Oncol"},{"key":"1735_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113277","author":"B-S Chung","year":"2022","unstructured":"Chung B-S, Liao I-C, Lin P-C, Wu S-Y, Kang J-W, Lin B-W, et al. PD-L1 expression in high-risk early-stage colorectal cancer-its clinical and biological significance in immune microenvironment. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232113277.","journal-title":"Int J Mol Sci"},{"key":"1735_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156144","volume":"273","author":"W-W Gao","year":"2025","unstructured":"Gao W-W, Zhou B, Chen X, Xu G-X, Zhang F, Zhang W. Expression and prognostic analysis of three clones of PD-L1 antibody in colorectal cancer. Pathol Res Pract. 2025;273:156144.","journal-title":"Pathol Res Pract"},{"key":"1735_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2023.152202","volume":"67","author":"Y Ba\u015f","year":"2023","unstructured":"Ba\u015f Y, Y\u0131lmaz B, G\u00fcney G, \u015eahin HHK, \u00d6z\u00e7erezci T, Ren\u00e7ber E, et al. Clinicopathological and prognostic significance of PD-L1 expression in colon adenocarcinoma tumor budding. Ann Diagn Pathol. 2023;67:152202.","journal-title":"Ann Diagn Pathol"},{"key":"1735_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0539-x","volume":"15","author":"Y Li","year":"2016","unstructured":"Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016;15:55.","journal-title":"Mol Cancer"},{"key":"1735_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12812-7","volume":"24","author":"H Nobin","year":"2024","unstructured":"Nobin H, Garvin S, Hagman H, Nodin B, Jirstr\u00f6m K, Brunnstr\u00f6m H. The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types. BMC Cancer. 2024;24:1051.","journal-title":"BMC Cancer"},{"key":"1735_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081943","author":"P Azcue","year":"2021","unstructured":"Azcue P, Enc\u00edo I, Guerrero Setas D, Suarez Alecha J, Galbete A, Mercado M, et al. PD-L1 as a prognostic factor in early-stage colon carcinoma within the immunohistochemical molecular subtype classification. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13081943.","journal-title":"Cancers (Basel)"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01735-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01735-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01735-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:02:43Z","timestamp":1767150163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-025-01735-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01735-x","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Ethics Committee on Health Research Ethics of Region Zealand (SJ-589) and registered in the Region Zealand record of processing activities related to scientific research projects (REG-124-2016). A waiver of informed consent for the included patients was approved by the Regional Ethics Committee on Health Research Ethics of Region Zealand. The study was performed in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TTE is employed at Visiopharm A\/S, Hoersholm, Denmark. The other authors declare that they have no competing interest related to the work described.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}